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Background: This bibliometric analysis aimed to identify and evaluate the 100 most-cited articles 
(T100 articles) on Sepsis syndrome. 
Method: The 100 most cited Sepsis syndrome-related articles were downloaded from Elsevier 
Scopus on 03.11.2020.  Each article were evaluated and described with the core information, 100 
Most cited documents, The 10 articles of our list with the highest citation per year (CY), Annual 
total citation per year, Most cited countries, Top10 Country-wise scientific production, Top  10 
Authors Production Over time, Top 10 Most relevant source and impacts are main subjects of the 
study. 
 
Results: The top 100 publications with highly cited articles are chosen for this analysis. The years 
2003 and 2005 were the most productive and positive year during this research. Most of the best-
cited papers have been published in the New England Journal of Medicine (NEJM) and in The 
Lancet. In the top 100 highly cited articles the title: “Intensive insulin therapy in critically ill 
patients” got the highest citation with 7663 and published in 2001 followed by the title "COVID-
19: consider cytokine storm syndromes and immunosuppression" written by Mehta P published in 
2020, got the highest total Citation per Year with 1744. The highest number of total citations per 
article was 5972 from the year 2016. 
 
Conclusion:  A comprehensive list of the most cited studies on Sepsis syndrome disorders can be 
found in this review. This current approach is a way to acknowledge the classic Septic disease 
articles, provide insight into international leaders, and explain patterns in research on Septic 
disease syndrome. 
 




The septic disorder is a life-threatening illness due to the host's exaggeration of 
inflammation. Sepsis is one of the important drivers of illness and death in the hospital, affecting 
about half of all admissions to critical care and over a third of all US hospital deaths(Rhee et al. 
2017). Since their immune systems are not yet mature or compromised due to other bacterial, viral, 
and fungal diseases, sepsis impacted the lives of five million children every year1 Sepsis-lead to 
acute kidney injury (S-AKI) occurs in up to 47% of hospitalized patients and is associated with 
poor clinical studies(Xu et al. 2015). Third international consensus definitions for sepsis and septic 
shock have been reviewed. In brief, sepsis has now been revolutionized as life-threatening organ 
failure due to the host's dysregulated reaction to infection(Hattori et al. 2017).  However, the 
pathophysiological pathway in the development of sepsis-associated multiple organ dysfunction 
remains incompletely understood and the lack of adequate treatment for sepsis-key organ failure 
is a major obstacle in its clinical management. Although after years of the extensive clinical and 





Sepsis requires prompt treatment with intravenous fluids and antimicrobials. In an 
intensive care unit, continuing care often continues(Naghavi et al. 2017; Deutschman and Tracey 
2014). If an appropriate fluid replacement test is not sufficient to control blood pressure, it is 
important to use drugs that improve blood pressure. Mechanical ventilation and blood dialysis may 
be required to maintain the operation of the lungs and kidneys. For access to the bloodstream and 
to direct care, a central venous catheter and an arterial catheter can be positioned(Vos et al. 2017). 
Cardiac production and superior vena cava oxygen saturation are other helpful measurements. 
Unless other conditions prohibit such treatments, people with sepsis need preventative measures 
for deep vein thrombosis, stress ulcers, and pressure ulcers. Some people can benefit from strict 
insulin regulation of blood sugar levels. It is controversial to use corticosteroids, with some reports 
finding benefits and others, not(Annane et al. 2019).  
 
This article intended to find the usefulness of sepsis syndrome research over a period and 
their scholarly communication pattern among the highly cited articles of sepsis syndrome, the 
detailed analysis and results were discussed. 
 
 
SEARCH STRATEGY:  
The search method was designed to collect all applicable indexed articles published 
relevant to Sepsis. We performed our electronic search in Scopus on 3rd November 2020. 
Therefore, the required search terms were collected and combined to ensure the identification of 
all applicable manuscripts as follows: TITLE-ABS-KEY (sepsis  OR  "Blood Poisoning"  OR  
pyaemia*  OR  pyemia*  OR  pyohemia*  OR  septicemia  OR  "Severe Sepsis"  OR  "Sepsis 
syndrome"  OR  "Septic shock"  OR  "Septic infection"  OR  "Septic shock syndrome"  OR  "Sepsis 
spectrum syndrome" ) 
 
 
SELECTION CRITERIA AND DATA EXTRACTION: 
The research included all studies whose main subject was sepsis. Publications were sorted 
based on the Scopus rank feature according to the highest citation number, and the top 100 were 
chosen. Further analysis was made to obtain the following items: Most cited documents, top 10 
highest citation articles, year-wise Annual total citation, most cited countries, Country-wise 
scientific production, Authors Production Over time, Most relevant source and impacts. The data 
was downloaded from the Scopus database as a RIS file and proceeded for further analysis.  All 
tables and data were analyzed using the R studio Bibliometrix (Biblioshiny) software. Bibliometrix 
has developed open-source software for quantitative research in Scientometric and Bibliometric 
analysis.   
 
THE LATEST EVOLUTION OF SEPSIS: 
According to the Lawson Health Research Institute, the best available solution to the 
treatment of sepsis works approximately six percent of the time, although preliminary findings 
indicate that potential developmental treatment in London, Ontario, could be successful in 40 
percent of cases. Sepsis is caused by an infection with microbial pathogens such as a virus or 
bacterium and entails a runaway infection that spreads across the body, causes death to organ 
failure, and has been described as a complication of COV(Jacquelyn LeBel 2020).  Researchers 
have shown that extracellular DNA, one of the factors responsible for the development of COVID-
19, can serve as a likely target for the treatment of sepsis-induced SARS-CoV-2 virus(Aradhana 
Subramanian 2020). The Center for Molecular Immunology (CIM) of Cuba has announced the 
launch of a new phase I and II study to determine the safety and effect of the Itolizumab therapeutic 




The total outcome results in our search are n=2,39,922. We selected the top 100 highest 
cited articles for analysis between 1976 and 3rd November 2020. The total number of citations was 
n=273306 between 7663 and 1487. All articles were published between 1976 and 2020. The 
average citation number per document n=2733. Total Number of Authors contributed to the top 
100 highly cited articles n=4381, single-author n=6, multi authors n=4375 (Table No.1). The most-
cited article was “Intensive insulin therapy in critically ill patients” which was published in 
2001(Table No.2). The oldest article on the list was ranked number 39 (cited 2467 times) and was 
published in 1976 entitled "Radiological demarcation of cemented sockets in total hip 
replacement".   The highest citation per year article was ranked with (cited 1744 times) and was 
published in 2020 entitled "COVID-19: consider cytokine storm syndromes and 
immunosuppression" published by Mehta.P, Lancet (Table.No 3.) The year with the highest 
number of articles was 2003(n = 8), followed by 2003, 2004, 2006, 2008 each (n= 6).  The highest 
number of total citations accounted for in 2001 with 5 articles (n= 27518).(Table No.4) The USA 
got a high number of total citations with n=149177 and average article citations (n=2869) 
(Table.5). Out of all countries, the USA is the highest number of articles published in the hole 
analysis(n =628) followed by the UK (n=159).(table No.6) The first authors with the most 
occurrences were listed in table 7, Vincent JL (Université libre de Bruxelles ULB, Brussels, 
Belgium) has acted as the first authorship with 11 articles, citation (n=38502). (Table No.7) 
  
The Top 100 Cited Papers were published from 1976 to 2020 with citation numbers varying from 
7663 to 1487. The necessary information for the top 100 highest citations as shown in table no 1. 
Out of 100 papers, 42 numbers of sources such as Journals, Books, etc., are contributed. In the top 
100 articles, a total of 2703 keywords will be used in the article. Out of a total of 100 highest cited 
publication Articles n=65, conference paper n=5, letter n=1, Review n=29 is included. 
 
TABLE 1. MAIN INFORMATION 
 
Description Results Document types No 
Documents 100 Article 65 
Sources (Journals, Books, etc.) 42 Conference Paper 5 
Keywords (ID) 2703 Letter 1 
Author's Keywords (DE) 108 Review 29 
Period 1976 - 2020 Total  100 
Average citations per documents 2733   
Total Authors 4381   
Authors of single-authored documents 6   
Authors of multi-authored documents 4375   
Documents per Author 0.0228   
Authors per Document 43.8   
 
TABLE 2. LIST OF 100 MOST CITED DOCUMENTS. 
 





1.  New England Journal 
of Medicine 
“Intensive insulin therapy in critically ill 
patients” 
2001 7663 403.32 
2.  New England Journal 
of Medicine 
“Early goal-directed therapy in the 
treatment of severe sepsis and septic 
shock” 
2001 7204 379.16 
3.  Chest “Definitions for sepsis and organ failure 
and guidelines for the use of innovative 
therapies in sepsis” 
1992 6575 234.82 
4.  Critical Care 
Medicine 
“Epidemiology of severe sepsis in the 
United States: Analysis of incidence, 
outcome, and associated costs of care” 
2001 6017 316.68 
5.  Science “Defective LPS signaling in C3H/HeJ 
and C57BL/10ScCr mice: Mutations in 
Tlr4 gene” 
1998 5994 272.45 
6.  JAMA - Journal of 
the American 
Medical Association 
“The third international consensus 
definitions for sepsis and septic shock 
(sepsis-3)” 
2016 5972 1493 
7.  Intensive Care 
Medicine 
“The SOFA (Sepsis-related Organ 
Failure Assessment) score to describe 
organ dysfunction/failure” 
1996 5445 226.88 
8.  New England Journal 
of Medicine 
“The L-Arginine-Nitric Oxide Pathway” 1993 5403 200.11 
9.  AJIC: American 
Journal of Infection 
Control 
“CDC definitions for nosocomial 
infections, 1988” 
1988 4855 151.72 
10.  New England Journal 
of Medicine 
“Efficacy and safety of recombinant 
human activated protein C for severe 
sepsis” 
2001 4849 255.21 
11.  New England Journal 
of Medicine 
“The effect of cardiac resynchronization 
on morbidity and mortality in heart 
failure” 
2005 4752 316.8 
12.  Annual Review of 
Immunology 
“Function and activation of NF-κB in 
the immune system” 
1994 4443 170.88 
13.  New England Journal 
of Medicine 
“Nivolumab versus docetaxel in 
advanced squamous-cell non-small-cell 
lung cancer” 
2015 4432 886.4 
14.  New England Journal 
of Medicine 
“The epidemiology of sepsis in the 
United States from 1979 through 2000” 
2003 4361 256.53 
15.  Critical care 
medicine 
“American College of Chest 
Physicians/Society of Critical Care 
Medicine Consensus Conference: 
definitions for sepsis and organ failure 
1992 4248 151.71 
and guidelines for the use of innovative 
therapies in sepsis”. 
16.  Clinical Infectious 
Diseases 
“Infectious Diseases Society of 
America/American Thoracic Society 
Consensus Guidelines on the 
management of community-acquired 
pneumonia in adults” 
2007 4125 317.31 
17.  Cell “Pattern Recognition Receptors and 
Inflammation” 
2010 4124 412.4 
18.  Critical Care 
Medicine 
“2001 SCCM/ESICM/ACCP/ATS/SIS 
International Sepsis Definitions 
Conference” 
2003 4099 241.12 
19.  The Lancet “Global, regional, and national age-sex 
specific all-cause and cause-specific 
mortality for 240 causes of death, 1990-
2013: A systematic analysis for the 
Global Burden of Disease Study 2013” 
2015 4019 803.8 
20.  New England Journal 
of Medicine 
“Medical progress: Staphylococcus 
aureus infections” 
1998 3980 180.91 
21.  Journal of the 
American Medical 
Association 
“Actual Causes of Death in the United 
States, 2000” 
2004 3972 248.25 
22.  Critical Care 
Medicine 
“Surviving sepsis campaign: 
International guidelines for management 
of severe sepsis and septic shock: 2012” 
2013 3911 558.71 
23.  Critical Care 
Medicine 
“Surviving sepsis campaign: 
International guidelines for management 
of severe sepsis and septic shock: 2008” 
2008 3740 311.67 
24.  American Journal of 
Infection Control 
“CDC/NHSN surveillance definition of 
health care-associated infection and 
criteria for specific types of infections in 
the acute care setting” 
2008 3615 301.25 
25.  Critical Care 
Medicine 
“Duration of hypotension before 
initiation of effective antimicrobial 
therapy is the critical determinant of 
survival in human septic shock” 
2006 3381 241.5 
26.  New England Journal 
of Medicine 
“Intensive versus conventional glucose 
control in critically Ill patients 
2009 3232 293.82 
27.  Science “CD14, a receptor for complexes of 
lipopolysaccharide (LPS) and LPS 
binding protein” 
1990 3178 105.93 
28.  Clinical Infectious 
Diseases 
“Bad bugs, no drugs: No ESKAPE! An 
update from the Infectious Diseases 
Society of America” 
2009 3056 277.82 
29.  Clinical Infectious 
Diseases 
“Nosocomial bloodstream infections in 
US hospitals: Analysis of 24,179 cases 
2004 2991 186.94 
from a prospective nationwide 
surveillance study” 
30.  New England Journal 
of Medicine 
“The pathophysiology and treatment of 
sepsis” 
2003 2921 171.82 
31.  New England Journal 
of Medicine 
“Increased survival in pancreatic cancer 
with nab-paclitaxel plus gemcitabine” 
2013 2854 407.71 
32.  Intensive Care 
Medicine 
“Surviving sepsis campaign: 
International guidelines for management 
of severe sepsis and septic shock, 2012” 
2013 2824 403.43 
33.  Journal of Clinical 
Oncology 
“Erlotinib plus gemcitabine compared 
with gemcitabine alone in patients with 
advanced pancreatic cancer: A phase III 
trial of the National Cancer Institute of 
Canada Clinical Trials Group” 
2007 2796 215.08 
34.  Journal of Clinical 
Investigation 
“Macrophage plasticity and 
polarization: In vivo veritas” 
2012 2773 346.63 
35.  Science “HMG-1 as a late mediator of endotoxin 
lethality in mice” 
1999 2660 126.67 
36.  Nature Reviews 
Microbiology 
“Pathogenic Escherichia coli” 2004 2636 164.75 
37.  Journal of the 
American Medical 
Association 
“Acute renal failure in critically ill 
patients: A multinational, multicenter 
study” 
2005 2633 175.53 
38.  Nature 
Biotechnology 
“Antimicrobial and host-defense 
peptides as new anti-infective 
therapeutic strategies” 
2006 2542 181.57 
39.  Clinical Orthopaedics 
and Related Research 
“Radiological demarcation of cemented 
sockets in total hip replacement” 
1976 2464 56 
40.  Critical Care 
Medicine 
“Surviving Sepsis Campaign guidelines 
for management of severe sepsis and 
septic shock” 
2004 2384 149 
41.  Journal of the 
American Medical 
Association 
“Effect of treatment with low doses of 
hydrocortisone and fludrocortisone on 
mortality in patients with septic shock” 
2002 2358 131 
42.  New England Journal 
of Medicine 
“Antiinflammatory therapy with 
canakinumab for atherosclerotic 
disease” 
2017 2310 770 
43.  Nature “Cloning of a new cytokine that induces 
IFN-γ production by T cells” 
1995 2275 91 
44.  The Lancet “Global, regional, and national causes of 
child mortality: An updated systematic 
analysis for 2010 with time trends since 
2000” 
2012 2217 277.13 
45.  Circulation “Percutaneous transcatheter 
implantation of an aortic valve 
2002 2209 122.72 
prosthesis for calcific aortic stenosis: 
First human case description” 
46.  New England Journal 
of Medicine 
“A comparison of continuous 
intravenous epoprostenol (prostacyclin) 
with conventional therapy for primary 
pulmonary hypertension” 
1996 2202 91.75 
47.  Lancet “WHO analysis of causes of maternal 
death: a systematic review” 
2006 2190 156.43 
48.  Microbiological 
Reviews 
“Listeria monocytogenes, a food-borne 
pathogen” 
1991 2180 75.17 
49.  The Lancet “Prednisone plus cabazitaxel or 
mitoxantrone for metastatic castration-
resistant prostate cancer progressing 
after docetaxel treatment: A randomised 
open-label trial” 
2010 2174 217.4 
50.  New England Journal 
of Medicine 
“Intensive insulin therapy and 
pentastarch resuscitation in severe 
sepsis” 
2008 2157 179.75 
51.  Science “The crisis in antibiotic resistance” 1992 2134 76.21 
52.  Blood “Interleukin-1 and interleukin-1 
antagonism” 
1991 2079 71.69 
53.  New England Journal 
of Medicine 
“Bortezomib or high-dose 
dexamethasone for relapsed multiple 
myeloma” 
2005 2059 137.27 
54.  New England Journal 
of Medicine 
“Infliximab, azathioprine, or 
combination therapy for Crohn's 
disease” 
2010 2021 202.1 
55.  Nature “Nicotinic acetylcholine receptor α7 
subunit is an essential regulator of 
inflammation” 
2003 2016 118.59 
56.  New England Journal 
of Medicine 
“Efficacy of B-cell-targeted therapy 
with rituximab in patients with 
rheumatoid arthritis” 
2004 1989 124.31 
57.  New England Journal 
of Medicine 
‘Platinum-based chemotherapy plus 
cetuximab in head and neck cancer” 
2008 1985 165.42 
58.  Pediatrics Breastfeeding and the use of human 
milk” 
2005 1982 132.13 
59.  Clinical 
Microbiology 
Reviews 
“Acinetobacter baumannii: Emergence 
of a successful pathogen” 
2008 1981 165.08 
60.  Nature “The immunopathogenesis of sepsis” 2002 1950 108.33 
61.  Nature “Anti-cachectin/TNF monoclonal 
antibodies prevent septic shock during 
lethal bacteraemia” 
1987 1938 58.73 
62.  Annual Review of 
Immunology 
“The host defense of Drosophila 
melanogaster” 
2007 1934 148.77 
63.  Intensive Care 
Medicine 
“Surviving Sepsis Campaign: 
International Guidelines for 
Management of Sepsis and Septic 
Shock: 2016” 
2017 1916 638.67 
64.  The Lancet “Global, regional, and national 
incidence, prevalence, and years lived 
with disability for 328 diseases and 
injuries for 195 countries, 1990-2016: A 
systematic analysis for the Global 
Burden of Disease Study 2016” 
2017 1889 629.67 
65.  Nature Reviews 
Immunology 
“Signalling pathways of the TNF 
superfamily: A double-edged sword” 
2003 1876 110.35 
66.  Nature “Circulating mitochondrial DAMPs 
cause inflammatory responses to injury” 
2010 1867 186.7 
67.  American Journal of 
Physiology - Cell 
Physiology 
“Physiological roles and properties of 
potassium channels in arterial smooth 
muscle” 
1995 1863 74.52 
68.  The Lancet “Global, regional, and national causes of 
child mortality in 2008: a systematic 
analysis” 
2010 1860 186 
69.  Lancet “Randomised double-blind placebo-
controlled study of interferon β-1a in 
relapsing/remitting multiple sclerosis” 
1998 1834 83.36 
70.  New England Journal 
of Medicine 
“Sildenafil citrate therapy for pulmonary 
arterial hypertension” 
2005 1827 121.8 
71.  Critical Care 
Medicine 
“Multiple organ dysfunction score: A 
reliable descriptor of a complex clinical 
outcome” 
1995 1819 72.76 
72.  Osteoarthritis and 
Cartilage 
“OARSI recommendations for the 
management of hip and knee 
osteoarthritis, Part II: OARSI evidence-
based, expert consensus guidelines” 
2008 1809 150.75 
73.  Cellular Signalling “LPS induction of gene expression in 
human monocytes” 
2001 1785 93.95 
74.  The Lancet “COVID-19: consider cytokine storm 
syndromes and immunosuppression” 
2020 1744 1744 
75.  Nature Reviews 
Immunology 
“High-mobility group box 1 protein 
(HMGB1): Nuclear weapon in the 
immune arsenal” 
2005 1741 116.07 
76.  Critical Care 
Medicine 
“Sepsis in European intensive care 
units: Results of the SOAP study” 
2006 1736 124 
77.  Pediatric Critical 
Care Medicine 
“International pediatric sepsis consensus 
conference: Definitions for sepsis and 
organ dysfunction in pediatrics” 
2005 1728 115.2 
78.  Proceedings of the 
National Academy of 
Sciences of the 
United States of 
America 
“Genomic responses in mouse models 
poorly mimic human inflammatory 
diseases” 
2013 1683 240.43 
79.  The Lancet “Early physical and occupational 
therapy in mechanically ventilated, 
critically ill patients: a randomised 
controlled trial” 
2009 1677 152.45 
80.  New England Journal 
of Medicine 
“Human infection with a novel avian-
origin” 
2013 1676 239.43 
81.  European Heart 
Journal 
“Nitric oxide synthases: Regulation and 
function” 
2012 1659 207.38 
82.  Physiological 
Reviews 
“Heme oxygenase-1/carbon monoxide: 
From basic science to therapeutic 
applications” 
2006 1640 117.14 
83.  New England Journal 
of Medicine 
“A Semiquantitative Culture Method for 
Identifying Intravenous-Catheter-
Related Infection” 
1977 1628 37.86 
84.  Intensive Care 
Medicine 
“2001 SCCM/ESICM/ACCP/ATS/SIS 
International Sepsis Definitions 
Conference” 
2003 1626 95.65 
85.  JAMA: The Journal 
of the American 
Medical Association 
“The Natural History of the Systemic 
Inflammatory Response Syndrome 
(SIRS): A Prospective Study” 
1995 1611 64.44 
86.  Lancet Infectious 
Diseases 
“The global burden of group A 
streptococcal diseases” 
2005 1609 107.27 
87.  The Lancet Global 
Health 
“Global causes of maternal death: A 
WHO systematic analysis” 
2014 1606 267.67 
88.  The Lancet “Burden of disease caused by 
Streptococcus pneumoniae in children 
younger than 5 years: global estimates” 
2009 1599 145.36 
89.  Gastroenterology “Adalimumab for Maintenance of 
Clinical Response and Remission in 
Patients With Crohn's Disease: The 
CHARM Trial” 
2007 1599 123 
90.  The Lancet “Global, regional, and national age-sex 
specifc mortality for 264 causes of 
death, 1980-2016: A systematic analysis 
for the Global Burden of Disease Study 
2016” 
2017 1597 532.33 
91.  Pharmacological 
Reviews 
“The sympathetic nerve - An integrative 
interface between two supersystems: 
The brain and the immune system” 
2000 1574 78.7 
92.  New England Journal 
of Medicine 
“Immediate versus delayed fluid 
resuscitation for hypotensive patients 
with penetrating torso injuries” 
1994 1565 60.19 
93.  Nature Immunology “Autophagy proteins regulate innate 
immune responses by inhibiting the 
release of mitochondrial DNA mediated 
by the NALP3 inflammasome” 
2011 1548 172 
94.  Journal of Clinical 
Oncology 
“Gemcitabine and cisplatin versus 
methotrexate, vinblastine, doxorubicin, 
and cisplatin in advanced or metastatic 
bladder cancer: Results of a large, 
randomized, multinational, multicenter, 
phase III study” 
2000 1548 77.4 
95.  Journal of Trauma - 
Injury, Infection and 
Critical Care 
“Problems in the management of type 
III (Severe) open fractures: A new 
classification of type III open fractures” 
1984 1544 42.89 
96.  New England Journal 
of Medicine 
“Nurse-staffing levels and the quality of 
care in hospitals” 
2002 1541 85.61 
97.  Hepatology “Diagnosis, Management, and 
Treatment of Hepatitis C” 
2004 1522 95.13 
98.  Lancet Oncology “CHOP-like chemotherapy plus 
rituximab versus CHOP-like 
chemotherapy alone in young patients 
with good-prognosis diffuse large-B-cell 
lymphoma: a randomised controlled trial 
by the MabThera International Trial 
(MInT) Group” 
2006 1512 108 
99.  New England Journal 
of Medicine 
“Pembrolizumab plus chemotherapy in 
metastatic non-small-cell lung cancer” 
2018 1498 749 
100.  The Lancet “High serum procalcitonin 
concentrations in patients with sepsis 
and infection” 
1993 1487 55.07 
 
Based on the number of citations in Table 2, the 100 top-cited on sepsis-related articles are 
listed by ranking order. It also indicates the number of citations per year. The most-cited article in 
this review is the one entitled "Intensive insulin therapy in critically ill patients" (2001)(Van Den 
Berghe et al. 2001), according to the overall citation count. The decade between 2001 and 2020 
was the most productive with 73 articles remaining 27 articles are published in before 2000. The 
articles were published in 42 different journals, more than four quarters of the articles (n=24) being 
published in the journal of New England Journal of Medicine (NEJM) followed by The Lancet 
n=10, Both of them accounted for 34 articles out of 100 (Table 2).  A total of 4381 authors were 
involved in the authorships, 6 were responsible for single-authored documents and 4375 were 
responsible for multi-authored documents. (Table No.1) The greatest count of top-cited 
publications was published in 2008 (n=8), 2003,2004,2006,2008 each (n=6). By the date of our 
search, these 100 articles were cited 273306 times in total, and the average citation per document 
was 2733 (Table No.1). Table No.2 shows that 2 articles with more than 7000 citation times cited 
in the journal of the New England Journal of Medicine in 2001.  
 
TABLE.3 THE 10 ARTICLES ON OUR LIST WITH THE HIGHEST CITATION PER YEAR 
(CY). 





Mehta P, Covid-19: “Consider Cytokine Storm Syndromes and 
Immunosuppression”, LANCET(Mehta et al. 2020) 
2020 1744 1744 
Singer M, “The Third International Consensus Definitions for 
Sepsis and Septic Shock (Sepsis-3)”, JAMA(Singer et al. 2016) 
2016 5972 1194.4 
Brahmer J, “Nivolumab Versus Docetaxel in Advanced 
Squamous-Cell Non-Small-Cell Lung Cancer”, NEW ENGL J 
MED(Brahmer et al. 2015) 
2015 4432 738.7 
Naghavi M, Global, “Regional, And National Age-Sex Specific 
All-Cause and Cause-Specific Mortality For 240 Causes of 
Death, 1990-2013: A Systematic Analysis for The Global 
Burden of Disease Study”, LANCET(Naghavi et al. 2015) 
2015 4019 669.8 
Ridker Pm, “Anti-inflammatory Therapy with Canakinumab for 
Atherosclerotic Disease”, NEW ENGL J MED(Ridker et al. 
2017) 
2017 2310 577.5 
Gandhi L, “Pembrolizumab Plus Chemotherapy In Metastatic 
Non-Small-Cell Lung Cancer”, NEW ENGL J MED(Gandhi et 
al. 2018) 
2018 1498 499.3 
Dellinger Rp, “Surviving Sepsis Campaign: International 
Guidelines for Management of Severe Sepsis and Septic 
Shock”: CRIT CARE MED(Dellinger et al. 2013) 
2013 3911 488.9 
Rhodes A, “Surviving Sepsis Campaign: International 
Guidelines for Management of Sepsis and Septic Shock”: 
INTENSIVE CARE MED(Rhodes et al. 2017) 
2017 1916 479 
Vos T, “Global, Regional, And National Incidence, Prevalence, 
And Years Lived with Disability For 328 Diseases and Injuries 
For 195 Countries, 1990-2016: A Systematic Analysis for The 
Global Burden of Disease Study”, LANCET(Vos et al. 2017) 
2017 1889 472.2 
Naghavi M, “Global, Regional, And National Age-Sex Specific 
Mortality For 264 Causes of Death, 1980-2016: A Systematic 
2017 1597 399.2 
Analysis for The Global Burden of Disease Study”, 
LANCET(Naghavi et al. 2015) 
 
Table 3 indicates the top 10 highly cited articles, the highest citation per year, record titles 
with citations. Mehta P et al, entitled “Covid-19: Consider Cytokine Storm Syndromes and 
Immunosuppression” published in 2020 in Lancet Journal and earned 1744 citations, preceded by 
Singer M, published in 2016 at Journal of the American Medical Association (JAMA), received 
1194.4 citations with the article title “The Third International Consensus Concepts for Sepsis and 
Septic Shock” (Sepsis-3). 
    
 
 
TABLE 4. YEAR-WISE ANNUAL TOTAL CITATION PER YEAR 
 






1976 1 2464 2464 56 44 
1977 1 1628 1628 37.86 43 
1978 0 0 0 0 0 
1979 0 0 0 0 0 
1980 0 0 0 0 0 
1981 0 0 0 0 0 
1982 0 0 0 0 0 
1983 0 0 0 0 0 
1984 1 1544 1544 42.89 36 
1985 0 0 0 0 0 
1986 0 0 0 0 0 
1987 1 1938 1938 58.73 33 
1988 1 4855 4855 151.72 32 
1989 0 0 0 0 0 
1990 1 3178 3178 105.93 30 
1991 2 4259 2129.5 73.43 29 
1992 3 12957 4319 154.25 28 
1993 2 6890 3445 127.59 27 
1994 2 6008 3004 115.54 26 
1995 4 7568 1892 75.68 25 
1996 2 7647 3823.5 159.31 24 
1997 0 0 0 0 0 
1998 3 11808 3936 178.91 22 
1999 1 2660 2660 126.67 21 
2000 2 3122 1561 78.05 20 
2001 5 27518 5503.6 289.66 19 
2002 4 8058 2014.5 111.92 18 
2003 6 16899 2816.5 165.68 17 
2004 6 15494 2582.333333 161.4 16 
2005 8 18331 2291.375 152.76 15 
2006 6 13001 2166.833333 154.77 14 
2007 4 10454 2613.5 201.04 13 
2008 6 15287 2547.833333 212.32 12 
2009 4 9564 2391 217.36 11 
2010 5 12046 2409.2 240.92 10 
2011 1 1548 1548 172 9 
2012 3 6649 2216.333333 277.04 8 
2013 5 12948 2589.6 369.94 7 
2014 1 1606 1606 267.67 6 
2015 2 8451 4225.5 845.1 5 
2016 1 5972 5972 1493 4 
2017 4 7712 1928 642.67 3 
2018 1 1498 1498 749 2 
2019 0 0 0 0 0 
2020 1 1744 1744 1744 1 
Total 100 273306 
   
 
Table 4 indicates the published year-wise citation of publications, the largest number of 
the citation (n=27518) for articles (n=5) published in 2001 accompanied by (n=18331) citations 
for articles (n=8) published in 2005. The highest number of citations per article for the year 2016 
(n=5972) followed by (n=5503.6) for the year 2001. The largest number of total quotations per 
year in 2020 was (n=1744) followed by 2016 (n=1493). There are no publications were present in 
the highly cited category from the year of 1978-1983, 1985 and 1986, 1989,1997,2019. 
 
TABLE 5. MOST CITED COUNTRIES 





USA N. America 149177 2869 
Canada N. America 18677 2668 
UK Europe 17152 2450 
Belgium Europe 15093 5031 
France Europe 13417 1917 
Germany Europe 9771 2443 
Japan Asia 6399 3200 
Australia Oceania 4841 2420 
Italy Europe 4600 2300 
Israel Asia 3848 1924 
TABLE 6. TOP10 COUNTRY WISE 
SCIENTIFIC PRODUCTION 
region  continent Freq percent 
USA N. America 628 26.55 
UK Europe 159 6.72 
Australia Oceania 143 6.05 
Germany Europe 107 4.52 
Canada N. America 99 4.19 
India Asia 85 3.59 
Iran Asia 68 2.88 
France Europe 64 2.71 
Italy Europe 59 2.49 
Ethiopia Africa 52 2.2 
Tables 5 and 6 show the most cited countries and country-wise scientific productions. The 
top three countries by publication citation counts were the USA (n=149177) Canada (n=18677) 
UK (n=17152) in table no.5. In the scientific production table.6 USA (n=625) got the highest 
number of author's country production followed by the UK (n=159).  European countries occupy 
the most numbers and are at the top of both tables 5 & 6. Countries in North America and Asia are 
second place in each table (Fig.1). 
 
Figure 1: country wise distribution of number of authors involved in the highly cited sepsis articles 
 
The journal with the highest number of top 100 cited articles was New England Journal of 
Medicine (n=2422), followed by The Lancet (n=10)  while their total citations is (n=76109) and 
(n=20263) respectively (Table 7).  Since the New England Journal of Medicine sepsis-related 
articles are published from 1977, It is one of the reasons for getting the highest number of citations.  
Cite score, SRJ, SNIP values are taken from Scopus. The Science journal got the highest number 
of Citations per article (n=3491.50) 
 









TC NP C/A PY 
Start 
New England Journal of 
Medicine 
66.1 18.291 13.212 76109 24 3171.21 1977 
The Lancet 73.4 14.554 21.313 20263 10 2026.30 1993 
Critical Care Medicine 10.6 2.994 2.310 31335 9 3481.67 1992 
Nature 51.0 14.047 8.820 10046 5 2009.20 1987 
Intensive Care Medicine 14.0 3.473 2.986 11811 4 2952.75 1996 
Science 45.3 13.110 7.521 13966 4 3491.50 1990 
Clinical Infectious 
Diseases 
12.5 4.226 2.888 10172 3 3390.67 2004 
Journal of The American 
Medical Association 
26.3 5.913 11.131 8963 3 2987.67 2002 
Annual Review of 
Immunology 
35.1 13.842 4.425 6377 2 3188.50 1994 
Journal of Clinical 
Oncology 
35.4 10.054 5.568 4344 2 2172.00 2000 
*TC-Total Citation, NP-Number of Publication, C/A-Citation Per Article 
  




TC NP PY_start 
Vincent JL Université libre de Bruxelles (ULB), 
Brussels, Belgium 
139 38502 11 1996 
Levy MM Rhode Island Hospital, Providence, 
United States 
68 26472 8 2003 
Marshall JC Ottawa Hospital Research Institute, 
Ottawa, Canada 
93 24551 8 1995 
Angus DC University of Pittsburgh, Pittsburgh, 
United States 
100 24380 6 2001 
Bernard GR Vanderbilt University Medical Center, 
Nashville, United State 
100 21291 6 1995 
Dellinger RP Cooper Medical School of Rowan 
University, Camden, United States 
54 21350 6 1992 
Gerlach H Vivantes Klinikum Neukölln, Berlin, 
Germany 
51 16511 6 2004 
Li, Yongmei Francisco Veterans Affairs Health Care 
System, San Francisco, United States 
38 9815 4 2015 
Annane, Djillali Hospital Raymond Poincare, Garches, 
France 
77 16981 5 2002 
Gupta R Indian Institute of Technology Kanpur, 
Kanpur, India 
90 7505 3 2015 
 
A total of 4381 authors (Authors of single-authored documents 6, Authors of multi-
authored documents 4375) (Table No.8) wrote these common articles, and their work laid the 
foundation for further study. The number of documents per author was 0.0228 and authors per 
document was 43.8.  The most frequently mentioned author in all articles was Vincent JL working 
in Université libre de Bruxelles (ULB), Brussels, Belgium with 11 articles.  More than half of the 







Figure 2: Top Authors production over the time 
 
DISCUSSION: 
Sepsis is an inflammatory immune reaction caused by bacteria. In most cases, fungal, 
bacterial, and protozoan infections spread sepsis(Deutschman and Tracey 2014). The lungs, brain, 
urinary tract, skin, and abdominal organs are common locations for the main infection. In this 
study, we evaluate the 100 most influential papers related to sepsis. The USA is the dominant 
country in terms of contribution to the developments of Sepsis research with the largest numbers 
of T100 articles. The journal New England Journal of Medicine published the T100 articles from 
1976 to 2020. This is held in our study in terms of the numbers of T100 articles, most cited 
countries, and Country wise scientific production demonstrating that the USA has made the 
greatest contribution to the development of sepsis research. (Table 5 & 6). Interestingly, the top 
two scientists, namely, Vincent JL and Levy MM, who published the most T100 articles as the 
first author, were from Belgium and the US, respectively. The author with the third-highest number 
of T100 articles in this study is the well-known Marshall JC from Ottawa Hospital Research 
Institute, Ottawa, Canada.  The largest number of the citation (Table No.4) for articles published 
in 2001 followed by 2005. The highest number of citations per article for the year 2016 followed 
for the year 2001. This study also clearly indicates that all the highly cited articles are directly 
involved in diagnosis and treatment oriented as well from reviews category. 
 
CONCLUSION: 
In recent decades, the standard treatment of Sepsis diseases has been affected and updated 
by the results of important studies. An internationally relevant clinical study aims to improve the 
use of antibiotics in sepsis risk patients with Covid-19(University 2020). This research shows that 
the developed countries, the United States, and European Countries are constantly advancing in 
the development of Sepsis research. There has been news that the care of sepsis patients is being 
delayed due to corona causes.  There is a very high chance that the number of research publications 
will decrease due to such reasons.  Research articles with the highest citations are written by 
western countries, developing countries like India, China, should pay more attention to the 
publication of research articles with high citations.  
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